Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Sarepta Therapeutics ( (SRPT) ) is now available.
On December 7, 2025, Sarepta Therapeutics‘ Board of Directors granted equity awards to CEO Douglas S. Ingram under the company’s 2018 Equity Incentive Plan. This marks the first equity grant for Mr. Ingram since 2017, with the award divided equally between time-based restricted stock units and performance-based awards, each valued at approximately $6 million. The performance-based portion is contingent on the company’s Incentive EBITDA performance over a two-year period, potentially doubling in value if targets are met, and is subject to Mr. Ingram’s continued service.
The most recent analyst rating on (SRPT) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.
Spark’s Take on SRPT Stock
According to Spark, TipRanks’ AI Analyst, SRPT is a Neutral.
Sarepta Therapeutics’ overall stock score is primarily impacted by its financial performance challenges, including inconsistent profitability and negative cash flows. Technical analysis provides a mixed outlook with short-term bullish momentum but potential bearish signals. Valuation remains a concern due to the negative P/E ratio. The earnings call offered some positive insights, but significant challenges persist.
To see Spark’s full report on SRPT stock, click here.
More about Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a biotechnology company focused on developing precision genetic medicine to treat rare diseases. The company primarily works on therapies for Duchenne muscular dystrophy and other neuromuscular diseases, leveraging its expertise in RNA-targeted therapies.
Average Trading Volume: 5,505,073
Technical Sentiment Signal: Sell
Current Market Cap: $2.33B
Learn more about SRPT stock on TipRanks’ Stock Analysis page.